New Retina Model Reveals How CLN3-Batten Disease Damages Vision and Points to a Treatment

Researchers have developed a new way to study CLN3-Batten disease (搜索)搜索该疾病, a rare, inherited condition that causes early vision loss in children followed by progressive neurological decline. Their findings, published in Science Translational Medicine, offer new insight into how the disease begins and point to a promising path for treatment.

Vision loss is often the first and most life-altering symptom for children with the disease, affecting their ability to read, learn, and navigate the world independently, often years before other neurological symptoms appear.

A Model That Mimics the Human Retina

Studying CLN3-Batten disease (搜索)搜索该疾病 has been challenging because the earliest damage occurs deep within the retina, a part of the eye that is difficult for researchers to access. To overcome this, researchers at University of Rochester Medicine (搜索)搜索该词条 created a 3D human stem cell-derived retina model that closely mimics how key parts of the eye work together—specifically, the interaction between light-sensing photoreceptors and support cells called the retinal pigment epithelium (RPE).

"Although molecular and cellular changes associated with the disease have been shown in other models, this retina model captures the earliest and most consistent pathology seen in patients, including photoreceptor outer segment loss and degeneration," said Ruchira Singh, PhD, an associate professor in the URochester Medicine Flaum Eye Institute and lead author of the study.

A New Understanding of How Damage Begins

While CLN3-Batten disease (搜索)搜索该疾病 has long been considered a neurodegenerative disorder—meaning researchers believed the primary damage occurred in neurons like photoreceptors—this new study reveals a more complex picture.

Using their model, the team showed that damage to RPE support cells alone can trigger photoreceptor degeneration. This suggests that the disease may begin when these support cells do not function properly. "Our data shows that primary RPE dysfunction is sufficient to instigate photoreceptor degeneration," Singh said. "This may help explain why vision loss is one of the earliest symptoms in CLN3-Batten disease (搜索)搜索该疾病."

A Key Biological Clue and a Potential Treatment

The researchers also identified a critical molecular problem in CLN3-Batten disease (搜索)搜索该疾病 cells: reduced levels of an enzyme called acid ceramidase查看药品详情 (AC), which helps regulate fats (lipids) inside cells. When AC levels drop, harmful lipid imbalances develop, contributing to retinal damage.

To address this, the team tested a potential treatment, recombinant human acid ceramidase查看药品详情 (rhAC), in both lab-grown retinas and a large-animal model of the disease. The results were encouraging, and the therapy improved cellular health and reduced signs of retinal degeneration. "rhAC is a strong therapeutic candidate because it restores enzyme activity in diseased cells without affecting healthy ones," said Singh.

What This Means for Future Treatments

Several therapies for CLN3 disease are already in development, including gene therapies and drugs targeting lipid metabolism. This new research could help improve those approaches by highlighting the importance of treating both photoreceptors and their supporting cells.

The new retina model also provides a powerful tool for testing potential therapies for CLN3-Batten disease (搜索)搜索该疾病 in a system that closely reflects human disease, and it may also model other retinal diseases that affect the photoreceptor-RPE tissue in the eye.

While the results are promising, more research is needed before this approach can be tested in patients. Future studies will focus on long-term safety and effectiveness, as well as whether this strategy could help address other aspects of the disease beyond vision loss.

The research was funded by the National Eye Institute, the ForeBatten Foundation, and the Mangurian Foundation.